Show simple item record

dc.contributor.authorLara, Beatriz
dc.contributor.authorCarnes, Anna
dc.contributor.authorDakterzada, Farida
dc.contributor.authorBenitez, Ivan
dc.contributor.authorPiñol Ripoll, Gerard
dc.date.accessioned2020-06-22T06:50:04Z
dc.date.issued2020
dc.identifier.issn1351-5101
dc.identifier.issn1468-1331
dc.identifier.urihttp://hdl.handle.net/10459.1/69071
dc.description.abstractBackground and purpose: The COVID epidemic is affecting individuals worldwide, and Alzheimer's disease (AD) and amnesic mild cognitive impairment (MCI) patients are at risk due to their characteristics and age. We analysed the impact of the pandemic on these patients' neuropsychiatric symptoms and their quality of life after five weeks of lockdown in Spain. Methods: We tested 40 subjects with a diagnosis of MCI (20) or mild AD (20) from the Cognitive Stimulation Program of Cognitive Disorders Unit. All patients had undergone a previous evaluation during the month before the lockdown, and they were re-evaluated after 5 weeks of lockdown. The Neuropsychiatric Inventory (NPI) and EuroQol-5D were used to evaluate the neuropsychiatric symptoms and quality of life of patients and caregivers. Results: The total baseline NPI score was 33.75 (22.28) vs 39.05 (27.96) after confinement (p=0.028). The most frequent neuropsychiatric symptoms affected were apathy (4.15 (3.78) vs 5.75 (4.02); p=0.002) and anxiety (3.95 (3.73) vs 5.30 (4.01); p=0.006) in MCI patients and apathy (2.35 (2.70) vs 3.75 (3.78); p=0.036), agitation (0.45 (1.14) vs 1.50 (2.66); p=0.029) and aberrant motor behaviour (1.25 (2.86) vs 2.00 (2.93); p=0.044) in AD patients. We did not observe differences in EuroQol-5D scores during the reevaluation. Approximately 30% of patients and 40% of caregivers reported a worsening of their health status during confinement. Conclusions: We have demonstrated the worsening of neuropsychiatric symptoms in patients with AD and MCI during 5 weeks of lockdown, with agitation, apathy and aberrant motor activity being the most affected symptoms.ca_ES
dc.description.sponsorshipThis study was supported by the Generalitat of Catalonia, Department of Health (PERIS 2019 SLT008/18/00050) to GPR; FD was supported by Agency for Management of University and Research Grants (FI_B100153).ca_ES
dc.language.isoengca_ES
dc.publisherWileyca_ES
dc.relation.isformatofVersió postprint del document publicat a https://doi.org/10.1111/ene.14339ca_ES
dc.relation.ispartofEuropean Journal of Neurology, 2020, vol. 27, p. 1744–1747ca_ES
dc.rights(c) Wiley, 2020ca_ES
dc.subjectAlzheimer’s diseaseca_ES
dc.subjectAnxietyca_ES
dc.subjectCoronavirusca_ES
dc.subjectCOVID‐19ca_ES
dc.subjectDepressionca_ES
dc.subjectMild Cognitive Impairmentca_ES
dc.titleNeuropsychiatric Symptoms and Quality of Life in Spanish Alzheimer's Disease Patients During COVID-19 Lockdownca_ES
dc.title.alternativeCOVID-19 and Alzheimer’s diseaseca_ES
dc.typeinfo:eu-repo/semantics/articleca_ES
dc.type.versioninfo:eu-repo/semantics/acceptedVersionca_ES
dc.rights.accessRightsinfo:eu-repo/semantics/embargoedAccessca_ES
dc.identifier.doihttps://doi.org/10.1111/ene.14339
dc.date.embargoEndDate2021-05-25


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record